The Role of mGluR5 in CBT-I
ConditionMajor Depressive Disorder (MDD)
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorStony Brook University
About this trial
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
Eligibility criteria
Qualifiers
capacity to provide informed consent,
at least 18 years of age
good physical health and absence of significant medical conditions,
diagnosis of major depressive disorder (MDD) with current major depressive episode as per DSM-5 criteria
Disqualifiers
currently taking effective antidepressants,
lifetime history of psychosis,
drug or alcohol dependence in the last 6 months or abuse in the last 2 months
unstable medical condition (i.e., condition not adequately stabilized for ≥ 3 months)
Trial design
Treatments tested in this trial
- Cognitive Behavioral Therapy for Insomnia
- PET Scan with [11C]ABP688
Treatment groups
42 Participants
are divided into 1 treatment groupSponsors and collaborators
Stony Brook University
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Mental Health (NIMH)
Collaborator
Source ClinicalTrials.gov